Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2020-2030F

Description

The Global Plasma Fractionation Market was valued at USD 25.78 Billion in 2024 and is projected to reach USD 36.82 Billion by 2030, growing at a CAGR of 6.32%. This growth is driven by the increasing reliance on plasma-derived therapies to manage chronic and rare conditions, including hemophilia, primary immunodeficiency disorders, and neurological diseases like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. The expanding elderly population and a higher prevalence of immune-related and bleeding disorders are contributing to the steady demand for plasma-based products such as immunoglobulins, albumin, and clotting factors.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 25.78 Billion
Market Size 2030	USD 36.82 Billion
CAGR 2025-2030	6.32%
Fastest Growing Segment	Albumin
Largest Market	North America

The continuous development of plasma collection infrastructure, especially across emerging economies, is further supporting market expansion. However, challenges such as high production costs, complex regulations, and prolonged manufacturing timelines hinder scalability. Additionally, competition from recombinant and biologic alternatives presents a threat to traditional plasma-based therapies.

Key Market Drivers

Growth in Healthcare Industry

The consistent expansion of the global healthcare industry is a fundamental driver of the plasma fractionation market. Generating more than USD 4 trillion annually, the industry sees strong contributions from pharmaceuticals and biotechnology at nearly USD 850 billion, and from diagnostics and medical technology at over USD 400 billion. These investments, along with improved infrastructure and wider access to services, are supporting the increasing use of plasma-derived treatments for conditions like immunodeficiencies, hemophilia, liver disease, and trauma-related bleeding.

By 2026, hospitals worldwide are projected to number 215,977, with growth mainly concentrated in the Far East & China and the Middle East & Africa. The expansion of hospitals and specialty clinics-especially in developing regions-is enhancing plasma collection and processing capabilities. This development is enabling a more stable global supply of fractionated products, while the rise in outpatient and personalized care models is also accelerating the adoption of these therapies.

Key Market Challenges

Limited Plasma Supply & Donation Infrastructure

A critical challenge in the plasma fractionation market is the limited availability of plasma due to underdeveloped donation systems. Plasma serves as the raw material for essential therapies such as immunoglobulins and clotting factors, yet its supply remains constrained by low donor participation and inconsistent infrastructure-particularly in lower-income countries.

In many regions, plasma collection systems are sparse or nonexistent, leading to an imbalance between growing therapeutic demand and available plasma volumes. Plasmapheresis procedures require specialized equipment, skilled staff, and time, which further limits capacity and scalability, especially in resource-limited settings.

Key Market Trends

Increasing Use of Plasma Fractionation in Autoimmune and Neurological Disorders

With over 57 million liters of plasma used annually to produce critical treatments, demand for plasma-derived therapies continues to climb-especially in managing autoimmune and neurological disorders. Conditions such as CIDP, Guillain-Barre syndrome, multiple sclerosis, and myasthenia gravis are increasingly treated with fractionated products, particularly intravenous immunoglobulin (IVIG), due to its immunomodulatory benefits.

IVIG has become a standard therapy for many of these conditions, backed by its inclusion in treatment guidelines and proven efficacy. Moreover, its use is expanding beyond conventional applications to address refractory cases and relapse prevention, reinforcing its growing role in neurology and chronic care management.

Key Market Players

Grifols S.A.
Octapharma AG
Intas Pharmaceuticals Ltd
LFB S.A.
Takeda Pharmaceutical Company Limited
CSL Limited
Biotest AG
Kedrion S.p.A
Bio Products Laboratory Ltd.
Bharat Serums and Vaccines Limited

Report Scope

In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasma Fractionation Market, By Product:

Albumin
Immunoglobulins
Coagulation Factors
Protease Inhibitors
Others

Plasma Fractionation Market, By Application:

Neurology
Hematology
Oncology
Immunology
Others

Plasma Fractionation Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Fractionation Market.

Available Customizations

Global Plasma Fractionation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Plasma Fractionation Market

5. Global Plasma Fractionation Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others)
- 5.2.2. By Application (Neurology, Hematology, Oncology, Immunology, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Plasma Fractionation Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Plasma Fractionation Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Application
- 6.3.2. Mexico Plasma Fractionation Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Application
- 6.3.3. Canada Plasma Fractionation Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Application

7. Europe Plasma Fractionation Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Plasma Fractionation Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Application
- 7.3.2. Germany Plasma Fractionation Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Plasma Fractionation Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Plasma Fractionation Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Plasma Fractionation Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Application

8. Asia Pacific Plasma Fractionation Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Plasma Fractionation Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Application
- 8.3.2. India Plasma Fractionation Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Application
- 8.3.3. South Korea Plasma Fractionation Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Application
- 8.3.4. Japan Plasma Fractionation Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Plasma Fractionation Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Application

9. South America Plasma Fractionation Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Plasma Fractionation Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Plasma Fractionation Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Plasma Fractionation Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Application

10. Middle East and Africa Plasma Fractionation Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Plasma Fractionation Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Plasma Fractionation Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Plasma Fractionation Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Plasma Fractionation Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. Grifols S.A.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. Octapharma AG
16.3. Intas Pharmaceuticals Ltd
16.4. LFB S.A.
16.5. Takeda Pharmaceutical Company Limited
16.6. CSL Limited
16.7. Biotest AG
16.8. Kedrion S.p.A
16.9. Bio Products Laboratory Ltd.
16.10. Bharat Serums and Vaccines Limited